Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Approves Shift from “Relative Contraindications” to “Contraindications” for 5 Drugs/Drug Groups
March 13, 2019
- Detailing Guidelines Casting Clouds over Drug Maker-Sponsored Press Seminars?
March 12, 2019
- Japan Issues 1st Guidance on Cancer Immunotherapy Development
March 11, 2019
- Govt to Ponder Appropriate Ways to Offer Off-Label Info to Patients
March 11, 2019
- LDP Wraps Up Review on Bill to Amend PMD Law; Cabinet OK Eyed in Mid-March
March 8, 2019
- LDP Panels Approve Proposal to Promote Regulatory Harmonization, Improve Access in Asia
March 8, 2019
- Chuikyo Approves Discussion Timeline for FY2020 Reimbursement Reform; Drug Pricing Debates Expected from June
March 7, 2019
- MHLW Grants Orphan Status to Adcetris, Evocalcet and More
March 6, 2019
- PMDA Sacks Employee for Doing Side Business with Companies with COI
March 5, 2019
- Xofluza Ordered to Add Hemorrhage Risk to Its Label
March 4, 2019
- Tagrisso Label Notes Previous Opdivo Use as Risk Factor for ILD
March 1, 2019
- MHLW to Impose Administrative Fines Only on Misleading Ads, Eyes 4.5% Charge: PMD Law
February 28, 2019
- MHLW Bureau Chief Eager to Hold Public-Private Confab towards 2020 Pricing Reform
February 28, 2019
- Kymriah Will Only Have Limited Impact on Health Finances: Minister
February 27, 2019
- Industry Official Prods Govt to Grant PMP to Repositioned Drugs Too
February 26, 2019
- Drug Prices Should Be Lowered in Areas with Needs Met, Like Lifestyle Disease: Prof.
February 26, 2019
- MHLW Panel Clears Biktarvy, Trelegy, Dupixent Asthma Use; Actemra OK’ed for CAR-T Side Effect
February 25, 2019
- Takecab, Clozaril under PMDA Risk Review
February 25, 2019
- MHLW Panel OKs Pfizer’s Vyndaqel for Sakigake-Designated Use
February 22, 2019
- Vyvanse Clears MHLW Panel after a Hold; Approval Expected in March
February 22, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…